IXICO plc Expansion of Collaboration with Biogen (8044L)
24 July 2017 - 4:00PM
UK Regulatory
TIDMIXI
RNS Number : 8044L
IXICO plc
24 July 2017
24 July 2017
IXICO plc
("IXICO" or the "Company")
Expansion of the commercial collaboration with Biogen and expert
institutions
Further enhancement of IXICO's Assessa(R) PML platform to
support pharmacovigilance reporting
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, announces an expansion of its pilot of the Assessa(R)
PML platform which includes Biogen, a leading company in Multiple
Sclerosis ("MS"), and expert reading institutions.
The Assessa(R) PML digital platform is being piloted in five EU
countries as part of a collaborative agreement which was announced
on 9 October 2015. The aim is to facilitate the remote transfer,
management and storage of MRI scans to more reliably and
effectively offer access to reading expertise for the detection of
Progressive Multifocal Leukoencephalopathy ("PML"), a rare and
potentially fatal disease that affects people living with MS. The
pilot, which includes platform development and on-boarding of
clinical sites participating in the pilot, has now been expanded to
include pharmacovigilance reporting (monitoring the effects of
medical drugs in order to identify and evaluate previously
unreported adverse reactions).
The total contribution paid or to be paid to IXICO and its
partners, associated with the scoping, development and pilot stages
of this partnership, is in the order of GBP1.5m, of which GBP0.8m
has been recognised from project inception to date. Subject to the
timing of the work being performed, the fees payable to IXICO
support the Company's confidence in delivering revenue growth in
the financial year ending 30 September 2017.
Giulio Cerroni, Chief Executive of IXICO, commented: "We are
delighted to announce the expansion of this pilot involving
clinical experts in specialist MS centres and Biogen. The
Assessa(R) PML digital platform is intended to provide technology
and speciality services to physicians involved in delivering care
to people living with MS. PML can be potentially fatal and IXICO is
proud to support those involved in its detection."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Tel: +44 20 3763
Officer 7499
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20 7408
Bidhi Bhoma/Edward Mansfield/ James 4090
Wolfe
FTI Consulting Limited (Investor Tel: +44 20 3727
Relations) 1000
Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
About Biogen
Through cutting-edge science and medicine, Biogen discovers,
develops and delivers worldwide innovative therapies for people
living with serious neurological, autoimmune and rare diseases.
Founded in 1978, Biogen is one of the world's oldest independent
biotechnology companies and patients worldwide benefit from its
leading multiple sclerosis and innovative hemophilia therapies.
More information is available on www.biogen.com.
About Assessa(R) PML
Assessa(R)PML is a digital companion product to provide
neurologists with second opinion reading services if there is a
suspicion of PML. This digital platform is based on IXICO's
existing Assessa(R) technology which has been further developed as
part of a collaboration including IXICO, clinical experts in
specialist centres in Europe , and with financial support from
Biogen Inc., (NASDAQ: BIIB).
About PML
Progressive multifocal leukoencephalopathy ('PML') is a rare and
potentially fatal brain infection, caused by the common John
Cunningham virus, which can arise in persons whose immune system is
weakened. PML has a typical mortality rate of 20-50 percent in the
first few months following diagnosis but this does depend on speed
of diagnosis, the severity of the underlying disease and treatment
received. Those who survive PML can be left with severe
neurological disabilities.
Some effective MS therapies that suppress a person's immune
system have known increased risk of PML. If identified early from
an MRI brain scan, PML can be treated by taking the patient off the
drug concerned. However, symptoms of PML and disease pathology
visible on MRI scans may be similar to those of a new MS lesion.
Neuroradiology expertise for assessment of suspected PML is seldom
available outside highly specialist centres.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFMGZNKMMGNZM
(END) Dow Jones Newswires
July 24, 2017 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From May 2024 to Jun 2024
Ixico (LSE:IXI)
Historical Stock Chart
From Jun 2023 to Jun 2024